Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06796907 · ClinicalTrials.gov registry record · Phase 1
A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)
A Phase 1 study, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 305
- Enrollment target
NCT06796907: Recruiting Phase 1 study, sponsored by GlaxoSmithKline.
NCT06796907 is a Phase 1 study that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 305 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (408% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06796907, a Phase 1 study, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 305 participants
- Enrollment target
Study Summary
Advanced solid tumors are cancers that have spread to other parts of the body. While many treatments exist, most people become resistant to them, and the cancer returns. Researchers are developing new treatments that combine different medicines for those who do not respond to single medicine. This study is looking at how safe and tolerable Mocertatug Rezetecan (Mo-Rez) is, how the body handles it, and how well it works when used with other cancer medicines. The study will include participants with advanced solid tumors who have either not responded to standard treatments or cannot tolerate them or have no available effective treatment.
Interventions
- DRUG Bevacizumab
- DRUG Dostarlimab
- DRUG Mo-Rez
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 305 participants |
| Start Date | 2025-03-04 |
| Est. Completion | 2028-10-10 |
| Phase | Phase 1 |
What NCT06796907 shows while recruiting
NCT06796907 is an interventional study that assigns participants to a tested intervention. The registered 305 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (408% higher).
The record links to 0 conditions, and to 3 interventions - of which Bevacizumab is the first listed.
NCT06796907 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06796907 about?
NCT06796907 is a clinical study titled "A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)". Advanced solid tumors are cancers that have spread to other parts of the body. While many treatments exist, most people become resistant to them, and the cancer returns. Researchers are developing new treatments that combine different medicines for those who do not respond to single medicine. This s...
What is the current status of trial NCT06796907?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 305 participants. The study started on 2025-03-04. Estimated completion is 2028-10-10.
What interventions are being tested in trial NCT06796907?
The interventions under investigation include: Bevacizumab (DRUG), Dostarlimab (DRUG), Mo-Rez (DRUG).
Who is sponsoring clinical trial NCT06796907?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06796907's enrollment target sits among peer trials
305 124th of 2000 higher than 1,877 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04107181 · 305 participants · NA
Pilot Study for Speculum Free Cervical Cancer Screening
- NCT05399056 · 305 participants · NA
Improving Participation in Pulmonary Rehabilitation Through Peer Support and Storytelling
- NCT05078970 · 306 participants · NA
Advancing Suicide Intervention Strategies for Teens During High Risk Periods
- NCT05843695 · 306 participants · NA
Enhancing Psychotherapy for Veterans and Service Members With PTSD and Anxiety
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI